CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kyto Technology and Life Science Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kyto Technology and Life Science Inc
13050 La Paloma Rd
Phone: (650) 204-7896p:650 204-7896 LOS ALTOS HILLS, CA  94022  United States Ticker: KBPHKBPH
This company ceased filing statements with the SEC on 5/12/2022.
Business Summary
Kyto Technology and Life Science, Inc. is an investment company focused on creating an exchange-traded fund (ETF)-like vehicle of diversified and thoroughly vetted start-ups thus defining an entirely new non-correlated asset class. The Company’s portfolio includes AbFero Pharmaceuticals Inc., Achelios Therapeutics, Inc., Altis Biosystems, AmplifiDX, AOA Inc., Astrocyte Pharmaceuticals Inc. and other.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20213/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
6289 Services allied with the exchange of securities or commodities

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer PaulRusso 78 1/8/2021 5/9/2018
Chief Financial Officer Simon P.Westbrook 72 3/15/2018 3/15/2018
Director MichaelBaghramian 79 1/8/2021 1/8/2021
Director Jon S.Saxe 87 1/8/2021 1/8/2021
Director Peter D.Staple 72 1/8/2021 1/8/2021

Business Names
Business Name
KBPH
KYTO BIOPHARMA INC
Kyto Biopharma Inc.

General Information
Outstanding Shares: 13,287,621 (As of 2/18/2022)
Shareholders: 150
Stock Exchange: OTC
Federal Tax Id: 651086538


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024